INSM•benzinga•
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast
Summary
BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by benzinga